Potassium2026-06

Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2/3 Randomized Controlled Trials.

Falodia Rahul, Alokozay Ehsanullah, Idrees Mohammad, Paghdar Darsh et al. — Clinical cardiology

Summary

This research reviewed studies on a new drug, Baxdrostat, for treating high blood pressure that hasn't responded to other treatments. It found the drug effectively lowers blood pressure but also significantly increases the risk of high potassium levels in the blood. Careful monitoring of potassium is essential for patients taking this medication.

AI-generated summary — read the original

Key points

Baxdrostat effectively lowers blood pressure in patients with resistant hypertension.
The drug significantly increases the risk of elevated potassium levels in the blood.
Potassium levels require careful monitoring when taking this medication.
More long-term studies are needed to fully understand its safety and benefits.

What the study looked at

This study aimed to understand how effective and safe a new drug called Baxdrostat is for people with high blood pressure that's difficult to control. Researchers specifically looked at its ability to lower blood pressure, its dose-response, and any side effects, particularly concerning potassium levels. The study was a systematic review and meta-analysis, meaning researchers combined and analyzed data from three existing high-quality randomized controlled trials (BrigHTN, BaxHTN, Bax24) involving 1285 participants. This approach allowed them to draw stronger conclusions by pooling results from multiple studies. They found that Baxdrostat significantly lowered blood pressure, with a clear dose-dependent effect. However, a notable finding was a five-fold increased risk of developing high potassium levels (hyperkalemia) in the blood. While this side effect can be managed with careful monitoring, the study noted that more long-term data is needed to fully assess its safety and suitability for widespread use.

Dietary takeaway

While a diet rich in potassium is generally recommended for blood pressure health, this study on a new medication shows that some drugs can significantly increase potassium levels in the body. For individuals prescribed such medications, it's vital to follow medical advice on potassium monitoring and discuss any dietary changes, as excessively high potassium can be dangerous. This research focuses on a specific drug, and general dietary guidelines for potassium should always be discussed with a healthcare professional, remembering that one study is not definitive.

Abstract

BACKGROUND: Baxdrostat is a selective aldosterone synthase (CYP11B2) inhibitor for treatment-resistant and uncontrolled hypertension, evaluated in phase 2/3 RCTs. OBJECTIVES: To estimate pooled placebo-corrected reductions in seated office and ambulatory SBP, characterize the dose-response relationship, assess cortisol selectivity, and quantify hyperkalemia risk. METHODS: We conducted a systematic review and meta-analysis of phase 2/3 randomized, double-blind, placebo-controlled trials of baxdrostat in hypertension, searching MEDLINE/PubMed, EMBASE, ClinicalTrials.gov, and NEJM.org to March 2026. The primary outcome was placebo-corrected change in seated office SBP, analyzed using random-effects meta-analysis (REML) with metafor in R. Risk of bias and certainty were evaluated using Cochrane RoB 2.0 and GRADE, respectively. RESULTS: Three RCTs (BrigHTN, BaxHTN, Bax24; N = 1285) were included. The pooled seated SBP reduction was -9.44 mmHg (95% CI: -11.09 to -7.79; I = 0.0%), with dose subgroup estimates of -8.57 mmHg (1 mg) and -10.11 mmHg (2 mg) and a clear dose-response in BrigHTN (slope -4.2 mmHg/mg; R = 0.96). Bax24 demonstrated a 24 h ambulatory SBP reduction of -14.0 mmHg (95% CI: -17.2 to -10.8). Serum cortisol was unsuppressed at all doses, while the pooled OR for potassium ≥ 6.0 mmol/L was 5.14 (95% CI: 1.76 to 14.97). GRADE certainty was moderate for seated SBP, low to moderate for ambulatory outcomes, and low for hyperkalemia. CONCLUSIONS: Baxdrostat produces meaningful, selective BP reductions across hypertensive populations. Hyperkalemia is manageable with structured monitoring. Certainty is limited by a few trials, a short follow-up, and safety imprecision. Long-term cardiovascular outcome data are needed before guideline incorporation.

View on PubMed →DOI: 10.1002/clc.70391